Completed PHASE1 INTERVENTIONAL 1-arm NCT02060396

Study of Biochemical Markers to Determine the Acetylsalicylic Acid Chemopreventive Effect Through Antiplatelet Action

Sponsor: Aragon Institute of Health Sciences

Updated 5 times since 2017 Last updated: Mar 17, 2014 Started: Apr 30, 2013 Primary completion: Jun 30, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02060396, this PHASE1 trial focuses on Healthy Volunteers and remains completed. Sponsored by Aragon Institute of Health Sciences, it has been updated 5 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aragon Institute of Health Sciences

Data source: Aragon Institute of Health Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zaragoza, Spain